Bluefin Capital Management, LLC Bristol Myers Squibb CO Transaction History

Bluefin Capital Management, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$68.48 - $81.09 $54,784 - $64,872	800 Added 11.03%	8,050 $579,000
Q3 2022 Nov 14, 2022	SELL	$0.13 - $76.84 $9,475 - $5.6 Million	-72,888 Reduced 90.95%	7,250 $515,000
Q2 2022 Aug 15, 2022	BUY	$72.62 - $79.98 $4.66 Million - $5.13 Million	64,138 Added 400.86%	80,138 $6.27 Million
Q1 2022 May 16, 2022	SELL	$61.48 - $73.72 $1.85 Million - $2.22 Million	-30,063 Reduced 65.26%	16,000 $1.17 Million
Q4 2021 Feb 14, 2022	SELL	$53.63 - $62.52 $56,740 - $66,146	-1,058 Reduced 2.25%	46,063 $2.87 Million
Q3 2021 Nov 15, 2021	SELL	$59.17 - $69.31 $258,099 - $302,330	-4,362 Reduced 8.47%	47,121 $2.79 Million
Q2 2021 Aug 16, 2021	BUY	$61.91 - $67.42 $1.2 Million - $1.31 Million	19,430 Added 60.62%	51,483 $3.44 Million
Q1 2021 May 17, 2021	SELL	$59.34 - $66.74 $2.25 Million - $2.54 Million	-37,995 Reduced 54.24%	32,053 $2.02 Million
Q4 2020 Feb 10, 2021	BUY	$57.74 - $65.43 $3.46 Million - $3.92 Million	59,952 Added 593.82%	70,048 $4.35 Million
Q3 2020 Nov 16, 2020	BUY	$57.43 - $63.64 $579,813 - $642,509	10,096 New	10,096 $609,000

2,428

1.5B

29.7M

32.2M

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $113B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

Get notified when there are updates to the investment portfolio of Bluefin Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Bluefin Capital Management, LLC with notifications on news.